Summit Therapeutics (SMMT) Profit After Tax Growth (1y) (2018 - 2026)

Summit Therapeutics (SMMT) Profit After Tax Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 0.26%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -107.76%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 101.22%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Summit Therapeutics 10.29 Bn 9.60 Bn - 61.88%

Historic Data

Download Data
DateValue
Jun 30, 2026 61.88%
Mar 31, 2026 -201.09%
Dec 31, 2025 -257.83%
Sep 30, 2025 -312.05%
Jun 30, 2025 -837.15%
Mar 31, 2025 -44.72%
Dec 31, 2024 -66.80%
Sep 30, 2024 -164.50%
Jun 30, 2024 -283.20%
Mar 31, 2024 91.98%
Dec 31, 2023 -101.50%
Sep 30, 2023 0.77%
Jun 30, 2023 6.04%
Mar 31, 2023 -2,242.17%
Dec 31, 2022 32.81%
Sep 30, 2022 -4.75%
Jun 30, 2022 31.31%
Mar 31, 2022 -32.42%
Dec 31, 2021 -142.15%
Sep 30, 2021 -15.32%